Wrapmanager Inc. Sells 245 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wrapmanager Inc. cut its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.7% in the fourth quarter, HoldingsChannel reports. The fund owned 2,048 shares of the pharmaceutical company’s stock after selling 245 shares during the period. Wrapmanager Inc.’s holdings in Vertex Pharmaceuticals were worth $825,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VRTX. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $27,000. Dunhill Financial LLC grew its holdings in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $33,000. Finally, Truvestments Capital LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter worth $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This represents a 0.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $481.65 on Tuesday. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market cap of $123.68 billion, a PE ratio of -218.93, a PEG ratio of 2.11 and a beta of 0.41. The company’s 50 day moving average price is $436.32 and its two-hundred day moving average price is $460.68. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on VRTX. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and raised their price target for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price on the stock. in a report on Thursday, January 30th. BMO Capital Markets set a $545.00 price objective on Vertex Pharmaceuticals in a research report on Friday, January 31st. Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.